Fig. 4.

Nilotinib reduces SJ-G2 growth and proliferation. Cell cultures treated with nilotinib were compared with vehicle-treated controls. Significant difference is indicated by * for p < 0.05, ** for p < 0.01, and *** for p < 0.001. a SJ-G2 cultures were exposed to nilotinib (0–10 μM) for 1–4 days. MTS assay demonstrated a dose-dependent effect on numbers of viable cells in culture. All treated cultures demonstrated significantly fewer viable cells compared to control, and a further difference was seen between 1 μM and ≥3 μM nilotinib treatment. b Durability of effect on cell numbers was evaluated by exposing SJ-G2 cultures to nilotinib (0–10 μM) for 2–14 days. Treated cultures exhibited fewer viable cells up to 14 days. c SJ-G2 cultures were exposed to nilotinib (0–10 μM) for 2–6 days. The number of viable cells, as determined by exclusion of trypan blue dye, was lower in the presence of nilotinib. d SJ-G2 cultures were exposed to nilotinib (0–10 μM) for 2–4 days. Incorporation of BrdU as detected by ELISA was decreased in treated cultures